Newsmax TV & Webwww.newsmax.comFREE - In Google Play
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
Tags: vioxx | merck | settlement | $950 | million | claims | off-label

Merck Settles Vioxx Claims for $950 Million

Wednesday, 23 November 2011 04:57 PM EST

Pharmaceutical giant Merck & Co. will pay roughly $950 million to settle claims that the company promoted Vioxx for rheumatoid arthritis before treatment for that condition was approved by the Food and Drug Administration.

The settlement is one of the largest in the nation over off-label promotion.

“We will not hesitate to pursue those who skirt the proper drug approval process and make misleading statements about the safety and efficacy of their products,” said Tony West, assistant attorney general for the U.S. Justice Department.

Merck said the settlement does not mean it admits any wrongdoing.

In 2007, the company also agreed to pay almost $5 billion to former Vioxx users who alleged the pill caused heart attacks. Vioxx was removed from the marketplace in September of 2004 after being linked to heart risks.

© HealthDay

The pharmaceutical giant has reached a settlement over claims it promoted off-label use of Vioxx for rheumatoid arthritis.
Wednesday, 23 November 2011 04:57 PM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
You May Also Like
Get Newsmax Text Alerts

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

© Newsmax Media, Inc.
All Rights Reserved
© Newsmax Media, Inc.
All Rights Reserved